12/3
10:37 am
lxrx
Lexicon Pharmaceuticals Has Multiple Paths To Upside, But Formidable Hurdles As Well [Seeking Alpha]
Low
Report
Lexicon Pharmaceuticals Has Multiple Paths To Upside, But Formidable Hurdles As Well [Seeking Alpha]
11/26
07:43 am
lxrx
Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences [Yahoo! Finance]
Low
Report
Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences [Yahoo! Finance]
11/25
06:03 pm
lxrx
Lexicon Pharmaceuticals, Inc. (LXRX) Makes Progress in Product Pipeline Development [Yahoo! Finance]
Low
Report
Lexicon Pharmaceuticals, Inc. (LXRX) Makes Progress in Product Pipeline Development [Yahoo! Finance]
11/25
08:30 am
lxrx
Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences
Low
Report
Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences
11/15
06:48 am
lxrx
Lexicon Pharmaceuticals: A Lottery Ticket With 3 Chances To Win [Seeking Alpha]
Low
Report
Lexicon Pharmaceuticals: A Lottery Ticket With 3 Chances To Win [Seeking Alpha]
11/11
08:30 am
lxrx
Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference
High
Report
Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference
11/8
02:47 pm
lxrx
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025 [Yahoo! Finance]
High
Report
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025 [Yahoo! Finance]
11/8
02:30 pm
lxrx
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025
High
Report
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025
11/6
07:30 am
lxrx
Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates
Low
Report
Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates
11/4
08:30 am
lxrx
Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association’s Sessions 2025 in New Orleans
Low
Report
Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association’s Sessions 2025 in New Orleans
10/30
08:30 am
lxrx
Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
Low
Report
Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
10/14
08:00 am
lxrx
Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit
Neutral
Report
Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit
10/9
09:30 am
lxrx
Former FDA, Industry Leaders Launch Canal Row Advisors to Provide Clients With Strategic Insight And Actionable Guidance In An Increasingly Complex Regulatory Landscape
High
Report
Former FDA, Industry Leaders Launch Canal Row Advisors to Provide Clients With Strategic Insight And Actionable Guidance In An Increasingly Complex Regulatory Landscape
10/8
08:12 am
lxrx
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain [Yahoo! Finance]
Low
Report
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain [Yahoo! Finance]
10/8
07:59 am
lxrx
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain
Medium
Report
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain
10/4
03:06 am
lxrx
Lexicon Pharmaceuticals (NASDAQ:LXRX) was upgraded by analysts at
Wall S
Medium
Report
Lexicon Pharmaceuticals (NASDAQ:LXRX) was upgraded by analysts at
Wall S
9/22
04:24 pm
lxrx
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes [Yahoo! Finance]
Low
Report
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes [Yahoo! Finance]
9/22
04:00 pm
lxrx
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
Medium
Report
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
9/17
07:00 am
lxrx
Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings
Low
Report
Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings
9/11
08:48 am
lxrx
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings [Yahoo! Finance]
Low
Report
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings [Yahoo! Finance]
9/11
08:30 am
lxrx
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings
Low
Report
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings
9/8
08:30 am
lxrx
Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
Low
Report
Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes